GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s cell-free DNA manufacturing technology to bolster the potential development of next-generation mRNA, cell, and viral gene therapies, as well as RNA-based vaccines. Elegen will receive upfront fees, purchase commitments, potential equity investment, and milestone payments as part of the agreement.
Elegen’s microfluidics-based technology, launched within a year, has already garnered dozens of customers, including major pharmaceutical companies, due to its improved speed, strand length, accuracy, and complexity in the DNA manufacturing process. The cell-free strategy streamlines the transition from discovery to clinical scale-up, saving time and resources that would typically be expended on cloning, linearization, and purification of plasmid DNA, as well as the creation of master cell banks.- Flcube.com
